Filing Flows › Editas Medicine (EDIT) › Q4 2024
Editas Medicine (EDIT) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 5, 2025
Editas Medicine (EDIT) reported revenue of $30.6M for the fourth quarter 2024 (Q4 2024), -49% from a year earlier and up 502-fold from the quarter before. Operating margin was -152.2%, net loss $45.4M (148.3% of revenue).
Editas Medicine, Q4 2024: revenue $30.6M (-49% year over year), operating margin -152.2%, net loss $45.4M, operating cash flow −$50.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $30.6M | 502× | -49% |
| Operating profit | −$46.6M | — | — |
| Net earnings | −$45.4M | — | — |
| Operating cash flow | −$50.8M | — | — |
What changed
Revenue was $30.6M in Q4 2024, down 49% year over year and up 50070% from the previous quarter.
Operating costs exceeded revenue by $46.6M, an operating margin of -152.2%. Total costs fell 8% while revenue fell 49%. The fastest-growing cost line was General & admin (+13%). The quarter ended with a net loss of $45.4M, narrower than the previous quarter's $62.1M loss.
Operating cash flow was −$50.8M. Non-cash charges added back $1.4M of depreciation and $4.0M of share-based compensation. Working capital and other items used $10.8M. Capital expenditures of $540K exceeded it, leaving free cash flow of −$51.3M.
Questions
What was Editas Medicine's revenue in the fourth quarter 2024?
Editas Medicine (EDIT) reported revenue of $30.6M for the fourth quarter 2024 (Q4 2024), -49% from a year earlier and up 502-fold from the quarter before.
Was Editas Medicine profitable in the fourth quarter 2024?
Operating loss was $46.6M (-152.2% of revenue) and net loss $45.4M.
Source: Editas Medicine 10-K on SEC EDGAR.